Nautilus Biotechnology (NAUT) Cash from Investing Activities (2020 - 2026)

Nautilus Biotechnology has reported Cash from Investing Activities for 7 years, with the latest figure at $12.0 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 16.94% year-over-year to $12.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $27.5 million (down 56.76% YoY) and the FY2025 annual result came in at $35.2 million, down 46.83% from the prior year.
• Cash from Investing Activities retreated to $12.0 million in Q2 2026 per NAUT's latest filing, from $14.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $37.1 million in Q4 2024 and troughed at -$64.1 million in Q4 2022.
• A 5-year average of $3.2 million and a median of $12.5 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities slumped 1156.32% in 2022, then soared 733.88% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$64.1 million in 2022, then surged by 35.9% to -$41.1 million in 2023, then surged by 190.37% to $37.1 million in 2024, then plunged by 97.88% to $787000.0 in 2025, then soared by 1427.57% to $12.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $12.0 million, $14.2 million, and $787000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.